MedPath

Kangpu's Novel Molecular Glue Modulator KPG-818 Receives IND Approval in China for Multiple Myeloma Treatment

• Kangpu Biopharmaceuticals has secured IND approval from China's NMPA for KPG-818, a novel oral molecular glue modulator targeting relapsed/refractory multiple myeloma.

• KPG-818 demonstrates potent degradation of Aiolos and Ikaros transcription factors, showing immunomodulatory, anti-angiogenic, and anti-tumor properties.

• Phase I trials in the US have shown promising safety and efficacy in heavily pretreated RRMM patients who previously received immunomodulatory drugs, proteasome inhibitors, and CD38 antibodies.

Kangpu Biopharmaceuticals announced today that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for KPG-818, advancing the treatment landscape for relapsed/refractory multiple myeloma (RRMM).

Mechanism of Action and Drug Properties

KPG-818 represents a novel approach in multiple myeloma treatment as an oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. The drug exhibits high binding affinity to cereblon (CRBN) and effectively triggers the degradation of Aiolos (IKZF3) and Ikaros (IKZF1), key zinc-finger transcription factors involved in B-cell development. This mechanism enables KPG-818 to deliver multiple therapeutic effects, including immunomodulation, anti-angiogenesis, and direct anti-tumor activity.

Promising Clinical Results

The completed Phase I clinical trial in the United States has yielded encouraging results for KPG-818 in treating various hematological tumors. The drug demonstrated favorable safety and tolerability profiles, along with promising pharmacokinetic characteristics. Notably, KPG-818 showed therapeutic potential in heavily pretreated RRMM patients who had previously undergone multiple lines of therapy, including:
  • Two immunomodulatory drugs (lenalidomide and pomalidomide)
  • At least one proteasome inhibitor (bortezomib, ixazomib, or carfilzomib)
  • A CD38 monoclonal antibody (daratumumab or isatuximab)

Development Pipeline and Company Focus

Kangpu Biopharmaceuticals, a clinical-stage biotechnology company, continues to advance its robust pipeline of potential first-in-class and best-in-class drug candidates. The company leverages proprietary technology platforms, including NeoMIDES®, gDACs®, and X-SYNERGY®, to develop innovative therapeutics targeting solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders.
The IND approval in China marks a significant milestone in KPG-818's development program and represents an important step forward in addressing the unmet needs of multiple myeloma patients who have exhausted current treatment options.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

InnoCare's BCL2 Inhibitor ICP-248 Combination Therapy Advances to Phase III Trial for First-line CLL/SLL Treatment in China

China's NMPA has approved InnoCare's registrational Phase III trial of BCL2 inhibitor ICP-248 (Mesutoclax) combined with orelabrutinib for first-line CLL/SLL treatment.
The ICP-248 and orelabrutinib combination demonstrated promising efficacy and safety in Phase II trials, offering potential for deeper remission in treatment-naïve CLL/SLL patients.

Tenaya Therapeutics Secures $8M CIRM Grant to Advance Gene Therapy Trial for Rare Heart Condition

Tenaya Therapeutics has received an $8 million CLIN2 grant from the California Institute for Regenerative Medicine to support their RIDGE-1 clinical trial of TN-401 gene therapy.
The Phase 1b trial targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), a severe genetic heart condition affecting an estimated 70,000 people in the U.S.

China NMPA Approves Astellas' Zolbetuximab for Advanced Gastric and GEJ Adenocarcinoma

China's NMPA has approved zolbetuximab (VYLOY™) for first-line treatment of HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Zolbetuximab is the first monoclonal antibody approved in China that targets the CLDN18.2 biomarker expressed in gastric tumor cells.

Japan Approves Lunsumio (mosunetuzumab) for Relapsed/Refractory Follicular Lymphoma

Chugai Pharmaceutical's Lunsumio (mosunetuzumab) has received approval in Japan for treating relapsed or refractory follicular lymphoma (R/R FL).
Lunsumio, a CD20/CD3 bispecific antibody, offers a novel monotherapy approach with potential for durable remission in patients who have failed two or more prior therapies.

Keytruda Approved in China for Early-Stage NSCLC Treatment

Keytruda gains approval in China for resectable stage II, IIIA, or IIIB NSCLC in combination with platinum-containing chemotherapy.
The approval is based on the KEYNOTE-671 trial, demonstrating a significant improvement in overall survival and event-free survival.

CureGene's Novel Antiplatelet Therapy CG-0255 Receives Clinical Trial Approval in China

CureGene's CG-0255, a novel antiplatelet drug, has received clinical trial approval in China for its injectable formulation, marking a significant step in its global development.
CG-0255 is designed for acute coronary syndrome patients undergoing percutaneous coronary intervention, offering a faster onset and enhanced efficacy compared to oral therapies.

Ruxoprubart Receives FDA IND Clearance for Phase II Trials in IgAN and Dermatomyositis

NovelMed's Ruxoprubart, a selective alternative complement pathway inhibitor, has received FDA IND clearance for a Phase II efficacy trial in Immunoglobulin A Nephropathy (IgAN).
Ruxoprubart also received FDA IND clearance for a Phase II trial for Dermatomyositis (DM), a rare autoimmune disorder affecting the skin and muscles.

Kangpu Biopharmaceuticals' KPG-818 Demonstrates Favorable Safety Profile in China Bridging Study

Kangpu Biopharmaceuticals completed a bridging clinical study of KPG-818 in healthy Chinese subjects, assessing safety, tolerability, and pharmacokinetics.
The randomized, double-blind, placebo-controlled trial evaluated multiple oral doses of KPG-818 over 14 days, with a 4-week follow-up period.

China Grants Breakthrough Therapy Designation to GSK's Blenrep for Multiple Myeloma

China's NMPA grants Breakthrough Therapy Designation (BTD) to GSK's Blenrep (belantamab mafodotin) combined with BorDex for relapsed or refractory multiple myeloma.
The BTD aims to expedite the development of treatments for severe diseases with limited options, showing potential for improved patient outcomes.

Relma-cel CAR-T Therapy Approved in China for Relapsed/Refractory Mantle Cell Lymphoma

Relma-cel (relmacabtagene autoleucel) has been approved in China for relapsed/refractory mantle cell lymphoma (MCL) in adults after two lines of systemic therapy.
The approval marks relma-cel as the first cell therapy approved for r/r MCL in China, based on a pivotal trial with an 81.36% objective response rate.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy